How Will Demands For Effectiveness Evidence Change Drug Development

The project reported in this Occasional Paper was intended to determine how changing demands for evidence are affecting drug development in five global pharmaceutical companies: Amgen, Eli Lilly, GSK, Novartis and Sanofi-Aventis. Read more here. (Source: OHE, 4/23/14).

You might also be interested in:

23andME CEO Talks Privacy, Deal with GSK September 11, 2018
Lilly Releases Report Detailing Humalog U100 Pricing March 25, 2019
Lilly Draws Criticism Amid Decision to Sell Cheaper Insulin Generic March 5, 2019
Amgen Responds to ICER's Request for Comment on Framework Update June 20, 2019
Reuters: CVS Adds Teva, Lilly Migraine Drugs February 1, 2019
P4AD: GSK is 'Abusing System' to Preserve Monopolies May 15, 2019
House Dems Launch Drug Pricing Investigation January 15, 2019